Cancer and Allergy; Molecular Association and Integrated Therapies
Abstract
Both innate and adaptive arms of immune system play role in tumor development. Moreover, genetic and epigenetic alterations, widely demonstrated in cancer cells, result in disturbances in molecular pathways regulating cell growth, survival, and metastasis. Knowledge of molecular and cellular mechanisms involved in carcinogenesis leads to improvement of targeted treatments for cancers. Similarly, allergies are immune related entities and are treated according to the molecular mechanisms of hypersensitivity reactions. Some studies support the hypothesis of inverse association between cancer and susceptibility for allergies but the correlation is not simple and some demonstrate positive relation. For example, in some studies histamine released in response to allergens plays a role in tumor progression, probably through maintaining survival of myeloid derived suppressor cells (MDSCs). However, in other studies, the protective role of IgE against carcinogenesis have been reported. In this review, the role of immune system and specific molecular mechanisms in cancer and allergy will be discussed. Based on separately mentioned factors, interactions between these two seemingly disparate entities will also be presented. We conducted this review to illustrate potential molecular and cellular mechanisms underlying the association of cancer and allergy and make a basis for future interventions.
1. Blair GE, Cook GP. Cancer and the immune system: an overview. Oncogene. 0000;27(45):5868-68.
2. Makkouk A, Weiner G. Cancer Immunotherapy and Breaking Immune Tolerance-New Approaches to an Old Challenge. Cancer res. 2015;75(1):5-10.
3. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell.100(1):57-70.
4. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance. Neoplasia. 2010;12(9):675-84.
5. Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, et al. Cancer stem cells and signaling pathways in radioresistance. Oncotarget. 2016;7(10):11002-17.
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627-44.
7. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143-53.
8. Zhang Y, Elgizouli M, Schöttker B, Holleczek B, Nieters A, Brenner H. Smoking-associated DNA methylation markers predict lung cancer incidence. Clin Epigenetics. 2016;8:127.
9. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008;63(10):1255-66.
10. Kumar S, Verma AK, Das M, Dwivedi PD. Molecular mechanisms of IgE mediated food allergy. Int Immunopharmacol. 2012;13(4):432-9.
11. Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GKT, et al. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J Leukoc Biol. 2014;96(1):151-9.
12. Sayour EJ, Mitchell DA. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res. 2017;2017:7.
13. He S, Yin T, Li D, Gao X, Wan Y, Ma X, et al. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med. 2013;11(1):186.
14. Du P, Xiong R, Li X, Jiang J. Immune Regulation and Antitumor Effect of TIM-1. J Immunol Res. 2016;2016:8605134.
15. Ivanova EA, Orekhov AN. T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. Biomed Res Int 2015;2015:327470.
16. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99(6):2114-21.
17. Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011;11:33.
18. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-7.
19. Lebrun J-J. The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Molecular Biology. 2012;2012:28.
20. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171(1):36-45.
21. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant. 2004;4(10):1614-27.
22. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40(11):2969-75.
23. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015;128:95-139.
24. Gabrilovich DI, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74.
25. Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2012;2(3):340-56.
26. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther. 2010;9(9):2450-7.
27. Noori-Daloii MR, Ebadi N. Pharmacogenomics and cancer stem cells. J Med Sci. 2015;25(1):1-15.
28. Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, et al. Identification of a subset of human non-small cell lung cancer patients with high PI3Kbeta and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014;20(3):595-603.
29. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392-433.
30. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68(17):6913-21.
31. Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol. 2009;4:127-50.
32. Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, et al. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 2013;3(8):908-21.
33. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-63.
34. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27(9):1394-400.
35. Handy DE, Castro R, Loscalzo J. Epigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease. Circulation. 2011;123(19):2145-56.
36. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153(3):590-600.
37. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013;123(12):5231-46.
38. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 2012;7(5):e37775.
39. Berger A. Th1 and Th2 responses: what are they? Bmj. 2000;321(7258):424.
40. Bettelli E, Kuchroo VK. IL-12– and IL-23–induced T helper cell subsets: birds of the same feather flock together. J Exp Med. 2005;201(2):169-71.
41. Maspi N, Abdoli A, Ghaffarifar F. Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog Glob Health. 2016;110(6):247-60.
42. Yuan M-L, Tong Z-H, Jin X-G, Zhang J-C, Wang X-J, Ma W-L, et al. Regulation of CD4+ T Cells by Pleural Mesothelial Cells via Adhesion Molecule-Dependent Mechanisms in Tuberculous Pleurisy. PLOS ONE. 2013;8(9):e74624.
43. Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252(1):104-15.
44. Goswami R, Kaplan MH. A Brief History of IL-9. J Immunol. 2011;186(6):3283.
45. Coquet JM, Rausch L, Borst J. The importance of co-stimulation in the orchestration of T helper cell differentiation. Immunol Cell Biol. 2015;93(9):780-88.
46. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60-.
47. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int 2016;65(3):243-52.
48. Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, et al. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease. J Immunol. 2013;190(11):5799-808.
49. Belkaid Y, Hand Timothy W. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157(1):121-41.
50. Brembilla NC, Dufour AM, Alvarez M, Hugues S, Montanari E, Truchetet M-E, et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 2016;75(9):1697.
51. Cesare AD, Meglio PD, Nestle FO. A Role for Th17 Cells in the Immunopathogenesis of Atopic Dermatitis? J Invest Dermatol. 2008;128(11):2569-71.
52. Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of T(h)1 and T(h)2 cell differentiation. Int Immunol. 2011;23(7):415-20.
53. Zhu J, Paul WE. Peripheral CD4 T cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev. 2010;238(1):247-62.
54. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006;107(10):3983-91.
55. van Hamburg JP, de Bruijn MJ, Ribeiro de Almeida C, van Zwam M, van Meurs M, de Haas E, et al. Enforced expression of GATA3 allows differentiation of IL-17-producing cells, but constrains Th17-mediated pathology. Eur J Immunol. 2008;38(9):2573-86.
56. Yagi R, Junttila IS, Wei G, Urban JF, Jr., Zhao K, Paul WE, et al. The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity. 2010;32(4):507-17.
57. Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. International Immunology. 2011;23(7):415-20.
58. Burt TD. Fetal Regulatory T Cells and Peripheral Immune Tolerance in. Am J Reprod Immunol. 2013;69(4):346-58.
59. Maggi E. T cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol. 2010;161(1):10-8.
60. Gorelik L, Constant S, Flavell RA. Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation. J Exp Med. 2002;195(11):1499-505.
61. Rachid R, Umetsu DT. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol. 2012;34(5):689-702.
62. Chen WJ, Jin W, Hardegen N, Lei K, Li L, Marinos N, et al. Conversion of Peripheral CD4(+)CD25(−) Naive T Cells to CD4(+)CD25(+) Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. J Exp Med. 2003;198(12):1875-86.
63. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DAA. The Development and Function of Regulatory T Cells. Cell Mol Life Sci. 2009;66(16):2603-22.
64. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neuro. 2008;4(7):384-98.
65. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121(6):1467-72, 72.e1.
66. Ganeshan K, Bryce PJ. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J Immunol. 2012;188(2):594-603.
67. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology. 2006;117(4):433-42.
68. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1).
69. Oral HB, Kotenko SV, Yilmaz M, Mani O, Zumkehr J, Blaser K, et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol. 2006;36(2):380-8.
70. Zhang H, Kong H, Zeng X, Guo L, Sun X, He S. Subsets of regulatory T cells and their roles in allergy. J Transl Med. 2014;12(1):125.
71. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008;63(11):1455-63.
72. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int. 2001;60(1):167-72.
73. Stone KD, Prussin C, Metcalfe DD. IgE, Mast Cells, Basophils, and Eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80.
74. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
75. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, et al. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med. 2005;202(6):751-60.
76. Singer J, Jensen-Jarolim E. IgE-based immunotherapy of cancer: challenges and chances. Allergy. 2014;69(2):137-49.
77. Daines MO, Zornes PA, Khurana Hershey GK. Signaling Interactions Between IL-4 or IL-13 and Leukotrienes in Allergic Inflammation. J Allergy Clin Immunol.119(1):S288.
78. Janeway CA Jr TP, Walport M immunobiology: The Immune System in Health and Disease. 5 ed. New York: Garland Science; 2001.
79. Allen JS, Eisma R, Leonard G, Kreutzer D. Interleukin-3 interleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps. Am J Otolaryngol. 1997;18(4):239-46.
80. Ala A, Dhillon A, Hodgson H. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. Int J Exp Pathol. 2003;84(1):1-16.
81. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE Enhances Mouse Mast Cell FcεRI Expression In Vitro and In Vivo: Evidence for a Novel Amplification Mechanism in IgE-dependent Reactions. J Exp Med. 1997;185(4):663-72.
82. Tezza G, Mazzei F, Boner A. Epigenetics of allergy. Early Hum Dev. 2013;89 Suppl 1:S20-1.
83. Jerrett M, Shankardass K, Berhane K, Gauderman WJ, Kunzli N, Avol E, et al. Traffic-related air pollution and asthma onset in children: a prospective cohort study with individual exposure measurement. Environ Health Perspect. 2008;116(10):1433-8.
84. Lovinsky-Desir S, Miller RL. Epigenetics, Asthma, and Allergic Diseases: A Review of the Latest Advancements. Curr Allergy Asthma Rep. 2012;12(3):211-20.
85. Koh BH, Hwang SS, Kim JY, Lee W, Kang MJ, Lee CG, et al. Th2 LCR is essential for regulation of Th2 cytokine genes and for pathogenesis of allergic asthma. Proc Natl Acad Sci U S A. 2010;107(23):10614-9.
86. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol. 2010;185(6):3489-97.
87. Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, et al. Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase. J Immunol. 2015;194(10):5014-21.
88. Kennedy L, Hodges K, Meng F, Alpini G, Francis H. Histamine and histamine receptor regulation of gastrointestinal cancers. Transl Gastrointest Cancer. 2012;1(3):215-27.
89. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol. 2010;161(4):755-67.
90. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243-50.
91. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: A novel concept with promise for the treatment of cancer. MAbs. 2014;6(1):54-72.
92. Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study. Mod Pathol. 2016;29(5):516-27.
93. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. Biomed Res Int. 2015;2015:142359.
94. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, et al. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci. 2005;98(4):450-8.
95. Reuter S, Martin H, Beckert H, Bros M, Montermann E, Belz C, et al. The Wnt/beta-catenin pathway attenuates experimental allergic airway disease. J Immunol. 2014;193(2):485-95.
96. Wan YY. GATA3: A master of many trades in immune regulation. Trends Immunol. 2014;35(6):233-42.
97. Purow B. NOTCH INHIBITION AS A PROMISING NEW APPROACH TO CANCER THERAPY. Adv Exp Med Biol. 2012;727:305-19.
98. Zhang W, Zhang X, Sheng A, Weng C, Zhu T, Zhao W, et al. γ-Secretase Inhibitor Alleviates Acute Airway Inflammation of Allergic Asthma in Mice by Downregulating Th17 Cell Differentiation. Mediat Inflamm. 2015;2015:7.
99. Tirado-Rodriguez B, Ortega E, Segura-Medina P, Huerta-Yepez S. TGF-β: An Important Mediator of Allergic Disease and a Molecule with Dual Activity in Cancer Development. J Immunol Res. 2014;2014:15.
100. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J Transl Med. 2012;10:183.
101. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol. 2007;85(5):348-56.
102. Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. 2002;307(1):1-14.
103. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-30.
104. Buffery D. The 2015 oncology drug pipeline: Innovation drives the race to cure cancer. Am Health Drug Benefits. 2015;8(4):216-22.
105. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48-51.
106. Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. J Immunol. 2014;192(3):859-66.
107. Hagströmer L, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123-27.
108. Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K, et al. Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation. Oncol Res. 2014;21(5):227-35.
109. Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol. 2010;28:445-89.
110. Chung F. Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediat Inflamm. 2001;10(2):51-59.
2. Makkouk A, Weiner G. Cancer Immunotherapy and Breaking Immune Tolerance-New Approaches to an Old Challenge. Cancer res. 2015;75(1):5-10.
3. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell.100(1):57-70.
4. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance. Neoplasia. 2010;12(9):675-84.
5. Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, et al. Cancer stem cells and signaling pathways in radioresistance. Oncotarget. 2016;7(10):11002-17.
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627-44.
7. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143-53.
8. Zhang Y, Elgizouli M, Schöttker B, Holleczek B, Nieters A, Brenner H. Smoking-associated DNA methylation markers predict lung cancer incidence. Clin Epigenetics. 2016;8:127.
9. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008;63(10):1255-66.
10. Kumar S, Verma AK, Das M, Dwivedi PD. Molecular mechanisms of IgE mediated food allergy. Int Immunopharmacol. 2012;13(4):432-9.
11. Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GKT, et al. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J Leukoc Biol. 2014;96(1):151-9.
12. Sayour EJ, Mitchell DA. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res. 2017;2017:7.
13. He S, Yin T, Li D, Gao X, Wan Y, Ma X, et al. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med. 2013;11(1):186.
14. Du P, Xiong R, Li X, Jiang J. Immune Regulation and Antitumor Effect of TIM-1. J Immunol Res. 2016;2016:8605134.
15. Ivanova EA, Orekhov AN. T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. Biomed Res Int 2015;2015:327470.
16. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99(6):2114-21.
17. Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011;11:33.
18. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-7.
19. Lebrun J-J. The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Molecular Biology. 2012;2012:28.
20. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171(1):36-45.
21. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant. 2004;4(10):1614-27.
22. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40(11):2969-75.
23. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015;128:95-139.
24. Gabrilovich DI, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74.
25. Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2012;2(3):340-56.
26. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther. 2010;9(9):2450-7.
27. Noori-Daloii MR, Ebadi N. Pharmacogenomics and cancer stem cells. J Med Sci. 2015;25(1):1-15.
28. Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, et al. Identification of a subset of human non-small cell lung cancer patients with high PI3Kbeta and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014;20(3):595-603.
29. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392-433.
30. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68(17):6913-21.
31. Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol. 2009;4:127-50.
32. Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, et al. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 2013;3(8):908-21.
33. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-63.
34. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27(9):1394-400.
35. Handy DE, Castro R, Loscalzo J. Epigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease. Circulation. 2011;123(19):2145-56.
36. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153(3):590-600.
37. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013;123(12):5231-46.
38. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 2012;7(5):e37775.
39. Berger A. Th1 and Th2 responses: what are they? Bmj. 2000;321(7258):424.
40. Bettelli E, Kuchroo VK. IL-12– and IL-23–induced T helper cell subsets: birds of the same feather flock together. J Exp Med. 2005;201(2):169-71.
41. Maspi N, Abdoli A, Ghaffarifar F. Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog Glob Health. 2016;110(6):247-60.
42. Yuan M-L, Tong Z-H, Jin X-G, Zhang J-C, Wang X-J, Ma W-L, et al. Regulation of CD4+ T Cells by Pleural Mesothelial Cells via Adhesion Molecule-Dependent Mechanisms in Tuberculous Pleurisy. PLOS ONE. 2013;8(9):e74624.
43. Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252(1):104-15.
44. Goswami R, Kaplan MH. A Brief History of IL-9. J Immunol. 2011;186(6):3283.
45. Coquet JM, Rausch L, Borst J. The importance of co-stimulation in the orchestration of T helper cell differentiation. Immunol Cell Biol. 2015;93(9):780-88.
46. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60-.
47. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int 2016;65(3):243-52.
48. Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, et al. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease. J Immunol. 2013;190(11):5799-808.
49. Belkaid Y, Hand Timothy W. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157(1):121-41.
50. Brembilla NC, Dufour AM, Alvarez M, Hugues S, Montanari E, Truchetet M-E, et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 2016;75(9):1697.
51. Cesare AD, Meglio PD, Nestle FO. A Role for Th17 Cells in the Immunopathogenesis of Atopic Dermatitis? J Invest Dermatol. 2008;128(11):2569-71.
52. Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of T(h)1 and T(h)2 cell differentiation. Int Immunol. 2011;23(7):415-20.
53. Zhu J, Paul WE. Peripheral CD4 T cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev. 2010;238(1):247-62.
54. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006;107(10):3983-91.
55. van Hamburg JP, de Bruijn MJ, Ribeiro de Almeida C, van Zwam M, van Meurs M, de Haas E, et al. Enforced expression of GATA3 allows differentiation of IL-17-producing cells, but constrains Th17-mediated pathology. Eur J Immunol. 2008;38(9):2573-86.
56. Yagi R, Junttila IS, Wei G, Urban JF, Jr., Zhao K, Paul WE, et al. The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity. 2010;32(4):507-17.
57. Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. International Immunology. 2011;23(7):415-20.
58. Burt TD. Fetal Regulatory T Cells and Peripheral Immune Tolerance in. Am J Reprod Immunol. 2013;69(4):346-58.
59. Maggi E. T cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol. 2010;161(1):10-8.
60. Gorelik L, Constant S, Flavell RA. Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation. J Exp Med. 2002;195(11):1499-505.
61. Rachid R, Umetsu DT. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol. 2012;34(5):689-702.
62. Chen WJ, Jin W, Hardegen N, Lei K, Li L, Marinos N, et al. Conversion of Peripheral CD4(+)CD25(−) Naive T Cells to CD4(+)CD25(+) Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. J Exp Med. 2003;198(12):1875-86.
63. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DAA. The Development and Function of Regulatory T Cells. Cell Mol Life Sci. 2009;66(16):2603-22.
64. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neuro. 2008;4(7):384-98.
65. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121(6):1467-72, 72.e1.
66. Ganeshan K, Bryce PJ. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J Immunol. 2012;188(2):594-603.
67. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology. 2006;117(4):433-42.
68. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1).
69. Oral HB, Kotenko SV, Yilmaz M, Mani O, Zumkehr J, Blaser K, et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol. 2006;36(2):380-8.
70. Zhang H, Kong H, Zeng X, Guo L, Sun X, He S. Subsets of regulatory T cells and their roles in allergy. J Transl Med. 2014;12(1):125.
71. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008;63(11):1455-63.
72. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int. 2001;60(1):167-72.
73. Stone KD, Prussin C, Metcalfe DD. IgE, Mast Cells, Basophils, and Eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80.
74. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
75. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, et al. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med. 2005;202(6):751-60.
76. Singer J, Jensen-Jarolim E. IgE-based immunotherapy of cancer: challenges and chances. Allergy. 2014;69(2):137-49.
77. Daines MO, Zornes PA, Khurana Hershey GK. Signaling Interactions Between IL-4 or IL-13 and Leukotrienes in Allergic Inflammation. J Allergy Clin Immunol.119(1):S288.
78. Janeway CA Jr TP, Walport M immunobiology: The Immune System in Health and Disease. 5 ed. New York: Garland Science; 2001.
79. Allen JS, Eisma R, Leonard G, Kreutzer D. Interleukin-3 interleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps. Am J Otolaryngol. 1997;18(4):239-46.
80. Ala A, Dhillon A, Hodgson H. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. Int J Exp Pathol. 2003;84(1):1-16.
81. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE Enhances Mouse Mast Cell FcεRI Expression In Vitro and In Vivo: Evidence for a Novel Amplification Mechanism in IgE-dependent Reactions. J Exp Med. 1997;185(4):663-72.
82. Tezza G, Mazzei F, Boner A. Epigenetics of allergy. Early Hum Dev. 2013;89 Suppl 1:S20-1.
83. Jerrett M, Shankardass K, Berhane K, Gauderman WJ, Kunzli N, Avol E, et al. Traffic-related air pollution and asthma onset in children: a prospective cohort study with individual exposure measurement. Environ Health Perspect. 2008;116(10):1433-8.
84. Lovinsky-Desir S, Miller RL. Epigenetics, Asthma, and Allergic Diseases: A Review of the Latest Advancements. Curr Allergy Asthma Rep. 2012;12(3):211-20.
85. Koh BH, Hwang SS, Kim JY, Lee W, Kang MJ, Lee CG, et al. Th2 LCR is essential for regulation of Th2 cytokine genes and for pathogenesis of allergic asthma. Proc Natl Acad Sci U S A. 2010;107(23):10614-9.
86. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol. 2010;185(6):3489-97.
87. Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, et al. Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase. J Immunol. 2015;194(10):5014-21.
88. Kennedy L, Hodges K, Meng F, Alpini G, Francis H. Histamine and histamine receptor regulation of gastrointestinal cancers. Transl Gastrointest Cancer. 2012;1(3):215-27.
89. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol. 2010;161(4):755-67.
90. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243-50.
91. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: A novel concept with promise for the treatment of cancer. MAbs. 2014;6(1):54-72.
92. Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study. Mod Pathol. 2016;29(5):516-27.
93. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. Biomed Res Int. 2015;2015:142359.
94. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, et al. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci. 2005;98(4):450-8.
95. Reuter S, Martin H, Beckert H, Bros M, Montermann E, Belz C, et al. The Wnt/beta-catenin pathway attenuates experimental allergic airway disease. J Immunol. 2014;193(2):485-95.
96. Wan YY. GATA3: A master of many trades in immune regulation. Trends Immunol. 2014;35(6):233-42.
97. Purow B. NOTCH INHIBITION AS A PROMISING NEW APPROACH TO CANCER THERAPY. Adv Exp Med Biol. 2012;727:305-19.
98. Zhang W, Zhang X, Sheng A, Weng C, Zhu T, Zhao W, et al. γ-Secretase Inhibitor Alleviates Acute Airway Inflammation of Allergic Asthma in Mice by Downregulating Th17 Cell Differentiation. Mediat Inflamm. 2015;2015:7.
99. Tirado-Rodriguez B, Ortega E, Segura-Medina P, Huerta-Yepez S. TGF-β: An Important Mediator of Allergic Disease and a Molecule with Dual Activity in Cancer Development. J Immunol Res. 2014;2014:15.
100. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J Transl Med. 2012;10:183.
101. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol. 2007;85(5):348-56.
102. Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. 2002;307(1):1-14.
103. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-30.
104. Buffery D. The 2015 oncology drug pipeline: Innovation drives the race to cure cancer. Am Health Drug Benefits. 2015;8(4):216-22.
105. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48-51.
106. Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. J Immunol. 2014;192(3):859-66.
107. Hagströmer L, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123-27.
108. Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K, et al. Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation. Oncol Res. 2014;21(5):227-35.
109. Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol. 2010;28:445-89.
110. Chung F. Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediat Inflamm. 2001;10(2):51-59.
| Files | ||
| Issue | Vol 4, No 4 (2021) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/igj.v4i4.12754 | |
| Keywords | ||
| Cancer Allergy Immune System Hypersensitivity Signaling Pathway Epigenetics | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Hemmati S, Baradaran Noveiry B, Keshavarz-Fathi M. Cancer and Allergy; Molecular Association and Integrated Therapies. Immunol Genet J. 2021;4(4):171-185.
